Omalizumab (Xolair) linked to Cardiovascular Adverse Events
February 14, 2010 by camh
Filed under Asthma, Medicine Cabinet
The popular asthma medication Xolair ,used in patients with moderate to severe asthma , was recently associated with adverse cardiovascular adverse events from the ongoing interim safety study entitled “Evaluating the Clinical Effectiveness and Long Term Safety in Patients with Moderate to Severe Asthma (EXCELS).”